I've spent four years making people care about medicines. Turns out the hard part isn't the science. It's the story.

SOHAIL KASMANI

Pharma brand management
Digital marketing · Healthcare innovation

"How do we get life-changing medicines to the patients who need them most?"

38% quarterly portfolio growth / £2.6M P&L owned at 25 / No.2 brand at GPs, up from rank 4 / 68,000+ people reached / 22,000+ patient screenings in 4 months / 2 promotions in 2.5 years / 4,600 ophthalmologists on Doctor's Day / Emerging Marketer of the Year, Alembic /
02

Five stories

Two pharma companies, one MBA, one nonprofit. These are the numbers I had to defend in real review meetings.

01 Alembic · Allergy · 2024 to 2025

The relaunch that took a challenger brand to No.2 at GPs

Vitaresp FX had been stuck at rank 4 for years while the big names split the market between them. When I took over the brand I rewrote the plan from scratch and relaunched it to 12,000 GPs and 2,000 ENT specialists. A year later it was the second most prescribed brand in its market at GPs, breathing down the leader's neck.

The insight that carried it: patients stopped taking the medicine after 3 days when they needed 4 weeks. So the campaign taught doctors and patients to finish the course. We called it 1-2-3-4, and it ran through everything from Rx pads to the "Goodbye Allergies, Hello Smiles" creative.

  • Cut the price and strip size so patients could actually afford the full course. Units grew 60%.
  • Moved the field force from print to digital visual aids and saved 30% on print and agency costs.
  • Won Emerging Marketer of the Year for this one.
0%Prescriber growth · 4,000 to 7,600
0%Unit growth
+0Share points · £1.7M sales
Brand strategyIQVIA analysisCampaign designPricing

Prescription rank at GPs 2023 to 2025

#1 #2 #3 #4 2023 2024 2025 No.2 at GPs

Rank in prescriptions among GPs in the represented market. Climbed from 4th to 2nd, then held it while the prescriber base grew 80%.

Vitaresp FX allergic rhinitis leave-behind literature for GPs
The literature GPs actually saw. Simple problem, simple picture.
02 Alembic · Anti-infectives · 2022 to 2025

Keeping a ₹40-crore antibiotic alive in a market shrinking 3% a year

Roxid carried 30% of the division's sales, and its whole category was in decline. Growth wasn't coming back, so I moved the money instead. The data said nobody was reading our printed material, so print got cut 77% and books went to zero. Everything saved went into the things doctors kept on their desks. Same total budget. Very different results.

  • Designed a 28-day field campaign the whole force could run. It generated 4,000 prescriptions.
  • Built an in-house reporting app because reps weren't reporting sales data. Compliance went from 52% to 93% in 8 months and the company rolled it out everywhere, across a 450-rep field force.
  • Sorted 22,000 tagged doctors into convert, consolidate and retain groups, each with its own playbook.
TurnaroundBudget reallocationField force toolsSegmentation

Promo budget, moved FY25 to FY26 plan

Print / LBL
-77%
Books
-100%
Brand reminders
+32%
Total spend
±0%

Every rupee moved from what wasn't working to what was.

Sales reporting compliance in-house app

52% FROM 52% · 8 MO

You can't manage a field force on data it never reports. The app made reporting easier than not reporting. 52% to 93%, adopted organisation-wide.

Roxid Right Choice leave-behind comparing roxithromycin and cefpodoxime pathogen by pathogen
The RIGHT CHOICE literature: roxithromycin vs cefpodoxime, pathogen by pathogen. The sharper claim the campaign was built on.
03 Cipla · Ophthalmology · 2025

Headhunted at 25 to run a £2.6M dry-eye portfolio

Cipla hired me before my MBA to run the Flogel range. The core problem took one week of doctor visits to spot: doctors treated every tear drop as the same thing, so our two brands read as interchangeable lubricants. We repositioned them by severity, following the clinical guidelines doctors already trusted. Flogel HA for surgery recovery. Flogel Hydra for moderate to severe disease. Each brand finally had one clear job.

  • Co-developed a screening tool with R&D that checked 22,000+ patients in four months.
  • Ran the top-50 KOL research myself, wrote the survey instruments, and turned an 8-brand category study into the launch plan.
  • Built the Anti-VEGF business case with projections out to FY30. It became the division's roadmap for retinal disease.
  • For Doctor's Day we turned 4,600 ophthalmologists' photos into personalised art cards. Dry Eye Month campaigns reached 68,000 people.
  • A rate analysis with Finance cut credit-note issuance by 25%.
0%Quarterly portfolio growth
0+Screenings in 4 months
0%Sales target, 40-person team

For awareness month I wrote six patient stories. Same arc, six different lives, so almost anyone scrolling would meet someone like themselves. Cipla's design team shipped them as carousels. Tap one:

P&L ownershipKOL researchContent strategyVeeva PromoMats
Doctor's Day card with a mosaic of doctor portraits, sent to 4,600 ophthalmologists
The Doctor's Day card. Each doctor's own photo, turned into art, printed and packed by territory.

Growth, quarter on quarter Flogel portfolio

0% QUARTERLY GROWTH

38% growth made Flogel the division's 3rd highest-contributing brand that quarter.

Flogel HA visual aid page with a post-surgery patient describing eye irritation
From the visual aid: a post-surgery patient, in her own words. That's the severity story doing its work.
04 Axial3D · MBA challenge · Brunel · 2026

The same service was priced $5 to $395 a case. We fixed that.

Axial3D turns patient scans into 3D surgical models. Brilliant product, chaotic pricing: the same case could be quoted at $5 or $395 depending on who wrote the quote. For my MBA business challenge we built them a value-based pricing strategy and a working quote engine, then presented it to the founder.

  • A rep enters seven deal inputs. The engine returns a customer-ready quote and an internal margin verdict.
  • Three-part model: annual platform fee, a per-case rate from a 4 specialty × 4 volume-tier matrix, and a one-time integration fee.
  • The finding that mattered: cardiology deals ran 84 to 87% margin while ortho ran 18 to 45%. Their margin problem was a portfolio-mix problem, not a discounting problem.
  • Stress-tested against three live deals worth $300K to $600K in year one.
Value-based pricingFinancial modellingDeal governance
The AXCEL quote tool in Excel: deal inputs on the left, the customer quote on the right, internal margin economics and the auto-approve verdict below
The actual tool. Inputs left, customer quote right, internal economics below. Cell B24 holds the approval verdict.

The quote engine 7 inputs, 1 verdict

INCustomer size · geography · case mix · committed volume · delivery model
01PLATFORM FEE, annual, sized to the customer band
02PER-CASE RATE, specialty by volume tier, anchored to value
03INTEGRATION FEE, one time, software deals only
OUTCustomer quote plus internal margin panel
Auto-approve Notify leadership Escalate to C-suite Below cost, do not send

Every quote lands in one of four bands. Pricing discipline a BD rep can run without a finance degree.

05 ACTAsia · Nonprofit · 2026 to now

576,000 children reached. 1,580 followers. Something was broken.

ACTAsia has taught compassion education across Asia for twenty years. More than half a million children have been through its programmes. When I arrived, its Instagram had 1,580 followers. I called that the 100x gap, and closing it is now my job. New positioning, a proper supporter funnel, and a year-long 20th anniversary campaign running April to December.

  • Walked the donation flow like a donor would. Found 5 clicks and 9 form fields between wanting to give and giving. Benchmarked 8 top charities and proposed fixes that ship in one engineering day.
  • Rebuilt the email programme by hand: 4 automated journeys, 8 flows each, 22 emails. Open rates went from 13% to 17%.
  • Set up an analytics pipeline and a monthly 5-competitor report, run with AI tools so a 4-person team can do a big team's job.
  • Supporter base up 10%, first-time conversion up 25%. Measured, not projected.
+0%First-time donor conversion
13%Email opens, from 13%
0Automated emails, hand-built
CROEmail automationGA4 + UTMAI-enabled ops

The 100x gap offline impact vs online voice

0
Children reached through compassion education
0
Instagram followers when I arrived

Twenty years of real-world impact, invisible online. Charities with similar missions hold 500K followers. That's not a content problem. It's a positioning and systems problem, and it's being fixed.

03

The writing

Occasional notes on brands, healthcare and the craft of marketing. New posts appear here on their own.

04

How I think

Five habits I keep coming back to. Each one comes with a receipt.

01

Diagnose before you prescribe.

Pharmacy school drills one thing into you: treatment without diagnosis is malpractice. Marketing without it is too. Every plan I write starts by asking what's actually wrong, which is rarely what the brief says is wrong.

Receipt

At Cipla the dry-eye range wasn't underperforming because of the product. Doctors just weren't sorting dry eye by severity, so I repositioned on the clinical algorithm they already trusted. At ACTAsia the diagnosis was the 100x gap between offline impact and online voice.

02

Segment until the message writes itself.

A message aimed at everyone lands with no one. I keep cutting the audience until each group's story becomes obvious. At that point the creative work is nearly done.

Receipt

Six dry-eye personas, one story arc, six lives. A traveller, a grandmother, a gardener, a designer, a surgery patient and a severe case. And 22,000 doctors sorted into convert, consolidate and retain, each with its own playbook.

03

Every tactic gets a number.

If an activity has no scale, no KPI and no month on the calendar, it's a wish. My brand plans run on one repeating structure: objective, scale, KPI, month by month tracker.

Receipt

"Grow the prescriber base" became 11,700 prescribers, 4,500 of them new, tracked monthly across 24 regions. The same habit produced the PCPM and YPM productivity metrics my teams used to compare territories fairly.

04

Kill what isn't working.

Most budgets are archaeology. Layer after layer of spend nobody has re-examined in years. I re-examine, publicly, with the data on the table. My own ideas included.

Receipt

Roxid's print spend, cut 77%. Books, cut entirely. The savings went into what prescribers actually responded to, at a flat total budget. My favourite finding from a what-didn't-work review: ENTs quietly ignored the steel tuning forks we gifted because they prefer brass. You only learn that by asking.

05

Build tools, not reports.

A report answers a question once. A tool answers it every week without me. When I catch myself doing the same analysis twice, I turn it into a system. These days AI sits in that loop.

Receipt

The reporting app that took compliance from 52% to 93%. The Axial3D quote engine. A daily sales flash that projects pace to target. And at ACTAsia, an analytics pipeline and a monthly 5-competitor report that replaced manual tracking entirely.

05

Say hello

Good brands are built in conversation.

I like talking about healthcare, brands, and why good marketing looks obvious in hindsight. If you're building something interesting, write to me. I'm in London and I reply fast.

Or just email sohailkasmani@gmail.com directly.